Crizotinib in ALK-positive lung cancer

被引：4
作者：
Girard, Nicolas [1 ]
机构：
[1] Louis Pradel Hosp, F-69500 Bron, France
来源：
LANCET ONCOLOGY | 2012年 / 13卷 / 10期
关键词：
ANAPLASTIC LYMPHOMA; CELL; KINASE;
D O I：
10.1016/S1470-2045(12)70375-3
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：962 / 963
页数：2
相关论文
共 50 条
  • [1] First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
    Solomon, Benjamin J.
    Mok, Tony
    Kim, Dong-Wan
    Wu, Yi-Long
    Nakagawa, Kazuhiko
    Mekhail, Tarek
    Felip, Enriqueta
    Cappuzzo, Federico
    Paolini, Jolanda
    Usari, Tiziana
    Iyer, Shrividya
    Reisman, Arlene
    Wilner, Keith D.
    Tursi, Jennifer
    Blackhall, Fiona
    Boyer, M.
    Ganju, V.
    Hughes, B.
    Pavlakis, N.
    Solomon, B.
    Varma, S.
    Berghmans, T.
    Canon, J-L
    Demedts, I.
    Janssens, A.
    Louis, R.
    Pieters, T.
    Schallier, D.
    Surmont, V.
    da Silva, C. Maciel
    Ferreira, C-G Moreira
    Hirsh, V.
    Joy, A.
    Laberge, F.
    Morzycki, W.
    Wierzbicki, R.
    Han, B.
    Liu, X.
    Qin, S.
    Shi, Y.
    Wang, Y.
    Wu, G.
    Wu, Y-L
    Zhou, C.
    Ahvonen, J.
    Barlesi, F.
    Cadranel, J.
    Dansin, E.
    Fayette, J.
    Morere, J-F
    NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (23) : 2167 - 2177
  • [2] Use of crizotinib for refractory ALK-positive lymphomas
    Shelikhova, L. N.
    Fominykh, V. V.
    Abramov, D. S.
    Myakova, N. V.
    Maschan, M. A.
    Maschan, A. A.
    TERAPEVTICHESKII ARKHIV, 2017, 89 (07) : 51 - 56
  • [3] A safety assessment of crizotinib in the treatment of ALK-positive NSCLC patients
    Dikopf, Alana
    Wood, Kevin
    Salgia, Ravi
    EXPERT OPINION ON DRUG SAFETY, 2015, 14 (03) : 485 - 493
  • [4] Emerging treatment for ALK-positive lung cancer
    Sharma, Janaki
    Pareek, Vipul
    Liu, Huijie
    Cheng, Haiying
    EXPERT OPINION ON EMERGING DRUGS, 2016, 21 (02) : 147 - 155
  • [5] Lorlatinib as a treatment for ALK-positive lung cancer
    Baba, Keisuke
    Goto, Yasushi
    FUTURE ONCOLOGY, 2022, 18 (24) : 2745 - 2766
  • [6] Hexokinases II-mediated glycolysis governs susceptibility to crizotinib in ALK-positive non-small cell lung cancer
    Lin, Caiyu
    Chen, Hengyi
    Han, Rui
    Li, Li
    Lu, Conghua
    Hao, Shuai
    Wang, Yubo
    He, Yong
    THORACIC CANCER, 2021, 12 (23) : 3184 - 3193
  • [7] Comparison of cardiovascular effects of crizotinib and chemotherapy in ALK-positive advanced non-small-cell lung cancer
    Wilner, Keith D.
    Usari, Tiziana
    Polli, Anna
    Kim, Elizabeth E.
    FUTURE ONCOLOGY, 2019, 15 (10) : 1097 - 1103
  • [8] Treatment of ALK-Positive Non-Small Cell Lung Cancer
    Bang, Yung-Jue
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2012, 136 (10) : 1201 - 1204
  • [9] Renal Effects of Crizotinib in Patients With ALK-Positive Advanced NSCLC
    Camidge, D. Ross
    Kim, Elizabeth E.
    Usari, Tiziana
    Polli, Anna
    Lewis, Iona
    Wilner, Keith D.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (06) : 1077 - 1085
  • [10] Crizotinib Versus Chemotherapy On ALK-positive NSCLC: A Systematic Review of Efficacy and Safety
    Wang, Mingxia
    Wang, Guanqi
    Ma, Haiyan
    Shan, Baoen
    CURRENT CANCER DRUG TARGETS, 2019, 19 (01) : 41 - 49
12345